

### AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

#### LISTING OF CLAIMS

- 1-14. Canceled
15. (Currently amended) A method of inhibiting the activity of a chemokine, said method comprising contacting a chemokine with an agent comprising a polypeptide selected from the group consisting of ~~THAP1~~ SEQ ID NO: 3, a polypeptide having at least ~~[[30%]]~~ 95% ~~amino-acid sequence~~ identity to ~~THAP1~~ SEQ ID NO: 3, a chemokine-binding domain of ~~THAP1~~ SEQ ID NO: 3 and a polypeptide having at least ~~[[30%]]~~ 95% ~~amino-acid sequence~~ identity to a chemokine-binding domain of ~~THAP1~~ SEQ ID NO: 3, wherein the activity of said chemokine is inhibited.
16. (Canceled)
17. (Original) The method of Claim 15, wherein said polypeptide is fused to an Fc region of an immunoglobulin.
18. (Original) The method of Claim 15, wherein said polypeptide comprises a THAP dimerization domain.
19. (Original) The method of Claim 18, wherein said THAP dimerization domain interacts with one or more THAP dimerization domains to form a THAP oligomer.
20. (Original) The method of Claim 15, wherein said polypeptide is a recombinant polypeptide.
21. (Original) The method of Claim 15, wherein said polypeptide binds to a chemokine selected from the group consisting of SLC, CCL19, CCL5, CXCL9 and CXCL10.
22. (Original) The method of Claim 15, wherein said polypeptide binds to a chemokine selected from the group consisting of SLC, CCL19 and CXCL9.
23. (Canceled)
24. (Currently amended) The method of Claim ~~23~~ 15, wherein said ~~THAP1~~ comprises the amino acid sequence of polypeptide is SEQ ID NO: 3.

25. (Currently amended) The method of Claim 15, wherein said polypeptide ~~comprises a polypeptide having at least 30% amino acid~~ has at least 95% sequence identity to THAP1 SEQ ID NO: 3.

26. (Currently amended) The method of Claim 15, wherein said polypeptide ~~comprises a chemokine-binding domain of THAP1~~ is a chemokine-binding domain of SEQ ID NO: 3.

27. (Currently amended) The method of Claim 26, wherein said chemokine-binding domain of ~~THAP1~~ SEQ ID NO: 3 comprises the amino acid sequence ~~of amino acids 143-213 of~~ SEQ ID NO: 3.

28. (Currently amended) The method of Claim 15, wherein said polypeptide ~~comprises a polypeptide having at least 30% amino acid identity to a chemokine-binding domain of THAP1~~ has at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3.

29-91. (Canceled)

92. (Previously presented) The method of Claim 15, wherein said polypeptide comprises an isolated polypeptide.

93. (Previously presented) The method of Claim 92, wherein said polypeptide binds to a chemokine selected from the group consisting of SLC, CCL19, CCL5, CXCL9 and CXCL10.

94. (Previously presented) The method of Claim 92, wherein said polypeptide binds to a chemokine selected from the group consisting of SLC, CCL19 and CXCL9.

95. (Currently amended) The method of Claim 92, wherein said polypeptide ~~comprises THAP1~~ is SEQ ID NO: 3.

96. (Currently amended) The method of Claim 92, wherein said polypeptide ~~comprises a polypeptide having at least 30% amino acid identity to THAP1~~ has at least 95% sequence identity to SEQ ID NO: 3.

97. (Currently amended) The method of Claim 92, wherein said polypeptide ~~comprises a chemokine-binding domain of THAP1~~ is a chemokine-binding domain of SEQ ID NO: 3.

98. (Currently amended) The method of Claim 92, wherein said polypeptide ~~comprises a polypeptide having at least 30% amino acid identity to a chemokine-binding domain of THAP1~~ has at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3.

99. (New) The method of Claim 15, wherein said polypeptide binds to CCL5.

100. (New) The method of Claim 92, wherein said polypeptide binds to CCL5.

101. (New) A method of binding a chemokine, said method comprising contacting a chemokine with an agent comprising a polypeptide selected from the group consisting of SEQ ID NO: 3, a polypeptide having at least 95% sequence identity to SEQ ID NO: 3, a chemokine-binding domain of SEQ ID NO: 3 and a polypeptide having at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3, wherein the chemokine is bound.

102. (New) The method of Claim 101, wherein said polypeptide is fused to an Fc region of an immunoglobulin.

103. (New) The method of Claim 101, wherein said polypeptide comprises a THAP dimerization domain.

104. (New) The method of Claim 103, wherein said THAP dimerization domain interacts with one or more THAP dimerization domains to form a THAP oligomer.

105. (New) The method of Claim 101, wherein said polypeptide is a recombinant polypeptide.

106. (New) The method of Claim 101, wherein said polypeptide binds to a chemokine selected from the group consisting of SLC, CCL19, CCL5, CXCL9 and CXCL10.

107. (New) The method of Claim 101, wherein said polypeptide binds to a chemokine selected from the group consisting of SLC, CCL19 and CXCL9.

108. (New) The method of Claim 101, wherein said polypeptide is SEQ ID NO: 3.

109. (New) The method of Claim 101, wherein said polypeptide has at least 95% sequence identity to SEQ ID NO: 3.

110. (New) The method of Claim 101, wherein said polypeptide is a chemokine-binding domain of SEQ ID NO: 3.

111. (New) The method of Claim 110, wherein said chemokine-binding domain of SEQ ID NO: 3 comprises the amino acid sequence 143-213 of SEQ ID NO: 3.

111. (New) The method of Claim 101, wherein said polypeptide has at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3.

113. (New) The method of Claim 101, wherein said polypeptide comprises an isolated polypeptide.

114. (New) The method of Claim 113, wherein said polypeptide binds to a chemokine selected from the group consisting of SLC, CCL19, CCL5, CXCL9 and CXCL10.

115. (New) The method of Claim 101, wherein said polypeptide binds to a chemokine selected from the group consisting of SLC, CCL19 and CXCL9.

116. (New) The method of Claim 101, wherein said polypeptide is SEQ ID NO: 3.

117. (New) The method of Claim 101, wherein said polypeptide has at least 95% sequence identity to SEQ ID NO: 3.

118. (New) The method of Claim 101, wherein said polypeptide is a chemokine-binding domain of SEQ ID NO: 3.

119. (New) The method of Claim 101, wherein said polypeptide has at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3.

120. (New) The method of Claim 101, wherein said polypeptide binds CCL5.

121. (New) The method of Claim 113, wherein said polypeptide binds CCL5.